X4 Pharmaceuticals (XFOR) Net Cash Flow Growth (5y) (2022 - 2025)
X4 Pharmaceuticals (XFOR) Net Cash Flow Growth (5y) (2022 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn |
| 10 | X4 Pharmaceuticals | 165.58 Mn | -51.47 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 75.15% |
| Sep 30, 2025 | 32.05% |
| Jun 30, 2025 | 36.37% |
| Mar 31, 2025 | -6.92% |
| Dec 31, 2024 | -22.97% |
| Sep 30, 2024 | -22.15% |
| Jun 30, 2024 | -6.00% |
| Mar 31, 2024 | -35.90% |
| Dec 31, 2023 | -80.27% |
| Sep 30, 2023 | -81.22% |
| Jun 30, 2023 | 35.91% |
| Mar 31, 2023 | -29.58% |
| Dec 31, 2022 | 35.51% |
| Sep 30, 2022 | 89.18% |
| Jun 30, 2022 | -21.62% |
| Mar 31, 2022 | -83.72% |